Manuel Pastor

Dr. Manuel Pastor

University Pompeu Fabra
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2000 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Manuel PastorManuel Pastor
Manuel Pastor
GCGabriele Cruciani
Gabriele Cruciani
IMIain McLay
Iain McLay
SPStephen Pickett
Stephen Pickett
SCSergio Clementi
Sergio Clementi

1 October 2000 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
GCGabriele Cruciani
Gabriele Cruciani
Manuel PastorManuel Pastor
Manuel Pastor
WGWolfgang Guba
Wolfgang Guba

25 July 2000 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MKMika A. Kastenholz
Mika A. Kastenholz
Manuel PastorManuel Pastor
Manuel Pastor
GCGabriele Cruciani
Gabriele Cruciani
EHEric E. J. Haaksma
Eric E. J. Haaksma
TFThomas Fox
Thomas Fox

28 November 2019 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
SESylvia E. Escher
Sylvia E. Escher
HKHennicke Kamp
Hennicke Kamp
SBSusanne H. Bennekou
Susanne H. Bennekou
ABAnnette Bitsch
Annette Bitsch
CFCiarán Fisher
Ciarán Fisher
DKDinant Kroese
Dinant Kroese

22 January 2016 in Scientific Reports
Verified
Journal Article
Open access
RGRamon Guixà-González
Ramon Guixà-González
MJMatti Javanainen
Matti Javanainen
MGMaricel Gomez-Soler
Maricel Gomez-Soler
BCBegoña Cordobilla
Begoña Cordobilla
JDJoan Domingo
Joan Domingo
JSJana Selent
Jana Selent
Membrane levels of docosahexaenoic acid (DHA), an essential omega-3 polyunsaturated fatty acid (ω-3 PUFA), are decreased in common neuropsychiatric disorders. DHA modulates key cell membrane properties like fluidity, thereby affecting the behaviour of transmembrane proteins like G protein-coupled receptors (GPCRs). These receptors, which have special relevance for major neuropsychiatric disorders have recently been shown to form dimers or higher order oligomers and evidence suggests that DHA levels affect GPCR function by modulating oligomerisation. In this study, we assessed the effect of membrane DHA content on the formation of a class of protein complexes with particular relevance for brain disease: adenosine A2A and dopamine D2 receptor oligomers. Using extensive multiscale computer modelling, we find a marked propensity of DHA for interaction with both A2A and D2 receptors, which leads to an increased rate of receptor oligomerisation. Bioluminescence resonance energy transfer (BRET) experiments performed on living cells suggest that this DHA effect on the oligomerisation of A2A and D2 receptors is purely kinetic. This work reveals for the first time that membrane ω-3 PUFAs play a key role in GPCR oligomerisation kinetics, which may have important implications for neuropsychiatric conditions like schizophrenia or Parkinson’s disease.

18 February 1998 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CPCarlos Pérez
Carlos Pérez
Manuel PastorManuel Pastor
Manuel Pastor
AOAngel R. Ortiz
Angel R. Ortiz
FGFederico Gago
Federico Gago